Private equity financing enabled the company to complete its purchase of P&A biotech.

OriGene Technologies raised $6.5 million, which allows it to complete the acquisition of Shenzhen P&A Biotech, a manufacturer and provider of mAbs. With the establishment of this technology center, OriGene will be able to develop genome-wide mAbs.

With OriGene’s China mAb production capacity and genome-wide resources, the company believes that it can produce several thousand high quality mAbs per year. This genome-wide mAb production capacity is available to all commercial and academic partners.

Over the last 10 years, OriGene developed the capacity to produce human full-length proteins from human cells. It has spent the last two years developing a genome wide collection of antigen standards and over 100,000 tissue samples for high-quality antibody validation.


To comment on this story, go to BLOGbiotech.

Previous articleMerck & Co. to Pay $130M for Insmed’s FOBs and Production Plants
Next articleBlog: A True Stimulus Package for Science and Technology